Telavancin: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m (Changed protection level for "Telavancin" ([Move=Allow only autoconfirmed users] (expires 15:41, 23 January 2014 (UTC)))) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Telavancin}} | |||
{{CMG}}; {{AE}} {{chetan}} | |||
} | |||
{{ | |||
==Overview== | |||
'''Telavancin''' is a [[bactericidal]] [[lipoglycopeptide]] under trial for use in [[MRSA]] or other [[Gram-positive]] infections. | '''Telavancin''' is a [[bactericidal]] [[lipoglycopeptide]] under trial for use in [[MRSA]] or other [[Gram-positive]] infections. | ||
On October 19, 2007, the [[United States|US]] [[Food and Drug Administration]] issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. <ref>{{cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= }}</ref> | On October 19, 2007, the [[United States|US]] [[Food and Drug Administration]] issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. <ref>{{cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= }}</ref> | ||
== | ==Category== | ||
Glycopeptide | |||
==US Brand Names== | |||
VIBATIV<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Telavancin description|Description]]''' | |||
'''| [[Telavancin clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Telavancin microbiology|Microbiology]]''' | |||
'''| [[Telavancin indications and usage|Indications and Usage]]''' | |||
'''| [[Telavancin contraindications|Contraindications]]''' | |||
'''| [[Telavancin warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Telavancin adverse reactions|Adverse Reactions]]''' | |||
'''| [[Telavancin drug interactions|Drug Interactions]]''' | |||
'''| [[Telavancin overdosage|Overdosage]]''' | |||
'''| [[Telavancin clinical studies|Clinical Studies]]''' | |||
'''| [[Telavancin dosage and administration|Dosage and Administration]]''' | |||
'''| [[Telavancin how supplied|How Supplied]]''' | |||
'''| [[Telavancin labels and packages|Labels and Packages]]''' | |||
{{ | ==Mechanism of Action== | ||
Like vancomycin, telavancin inhibits bacterial [[cell wall]] synthesis by binding to the <small>D</small>-[[Alanine|Ala]]-<small>D</small>-Ala terminus of the peptidoglycan in the growing cell wall (see [[Vancomycin#Pharmacology and chemistry|Pharmacology and chemistry of vancomycin]]). In addition, it disrupts bacterial [[Biological membrane|membranes]] by [[depolarization]].<ref name=HIG2005>{{Cite journal| url=http://aac.asm.org/cgi/content/full/49/3/1127| title=Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus| journal=Antimicrobial Agents and Chemotherapy| pages=1127–1134| volume=49| issue=3| year=2005| doi=10.1128/AAC.49.3.1127-1134.2005| pmid=15728913| last1=Higgins| first1=DL| last2=Chang| first2=R| last3=Debabov| first3=DV| last4=Leung| first4=J| last5=Wu| first5=T| last6=Krause| first6=KM| last7=Sandvik| first7=E| last8=Hubbard| first8=JM| last9=Kaniga| first9=K| pmc=549257}}</ref><ref>{{Cite journal | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | |||
Revision as of 22:55, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.
On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. [1]
Category
Glycopeptide
US Brand Names
VIBATIV®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Like vancomycin, telavancin inhibits bacterial cell wall synthesis by binding to the D-Ala-D-Ala terminus of the peptidoglycan in the growing cell wall (see Pharmacology and chemistry of vancomycin). In addition, it disrupts bacterial membranes by depolarization.[2]<ref>{{Cite journal
References
- ↑ "Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin". Retrieved 2008-03-08.
- ↑ Higgins, DL; Chang, R; Debabov, DV; Leung, J; Wu, T; Krause, KM; Sandvik, E; Hubbard, JM; Kaniga, K (2005). "Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus". Antimicrobial Agents and Chemotherapy. 49 (3): 1127–1134. doi:10.1128/AAC.49.3.1127-1134.2005. PMC 549257. PMID 15728913.